BCD 085

Drug Profile

BCD 085

Alternative Names: Anti-IL-17-monoclonal-antibody-Biocad; Anti-interleukin-17-monoclonal-antibody-Biocad; BCD-085

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Hepatoprotectants; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ankylosing spondylitis; Plaque psoriasis
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 25 Jul 2018 Biocad plans the PATERA phase III trial for Psoriatic Arthritis in Belarus and Russia , (NCT03598751)
  • 13 Jun 2018 Interim efficacy and adverse events data from a phase II trial in ankylosing spondylitis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 27 Apr 2018 Phase-II clinical trials in Primary biliary cirrhosis (Combination therapy) in Russia (SC) (NCT03476993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top